|
US6043275A
(en)
*
|
1998-04-16 |
2000-03-28 |
Ono Pharmaceutical Co., Ltd. |
3,7-dithiaprostanoic acid derivative
|
|
US6437146B1
(en)
|
1998-09-25 |
2002-08-20 |
Fujisawa Pharmaceutical Co., Ltd. |
Oxazole compounds as prostaglandin e2 agonists or antagonists
|
|
AU6427599A
(en)
*
|
1998-10-15 |
2000-05-01 |
Merck & Co., Inc. |
Methods for stimulating bone formation
|
|
US6414006B1
(en)
|
1998-10-15 |
2002-07-02 |
Merck Frosst Canada & Co. |
Methods for inhibiting bone resorption
|
|
CA2364948C
(en)
|
1999-03-05 |
2011-04-26 |
Duke University |
C16 unsaturated fp-selective prostaglandins analogs
|
|
CN1304319A
(zh)
*
|
1999-03-16 |
2001-07-18 |
东丽株式会社 |
子宫颈管成熟剂及子宫颈管成熟方法
|
|
US6894175B1
(en)
*
|
1999-08-04 |
2005-05-17 |
The Procter & Gamble Company |
2-Decarboxy-2-phosphinico prostaglandin derivatives and methods for their preparation and use
|
|
TWI247606B
(en)
*
|
1999-11-24 |
2006-01-21 |
Ono Pharmaceutical Co |
Treating agent for osteopenic diseases
|
|
JP4618548B2
(ja)
*
|
1999-11-24 |
2011-01-26 |
小野薬品工業株式会社 |
骨量低下疾患治療剤
|
|
BR0015781A
(pt)
*
|
1999-11-24 |
2002-12-31 |
Ono Pharmaceutical Co |
Composição farmacêutica para tratamento de doenças associadas à diminuição de massa óssea
|
|
ATE327751T1
(de)
|
2000-01-31 |
2006-06-15 |
Pfizer Prod Inc |
Verwendung von aktivatoren des prostaglandinrezeptores 4 zur behandlung von akuter oder chronischer niereninsuffizienz
|
|
US20020013294A1
(en)
|
2000-03-31 |
2002-01-31 |
Delong Mitchell Anthony |
Cosmetic and pharmaceutical compositions and methods using 2-decarboxy-2-phosphinico derivatives
|
|
US20020172693A1
(en)
*
|
2000-03-31 |
2002-11-21 |
Delong Michell Anthony |
Compositions and methods for treating hair loss using non-naturally occurring prostaglandins
|
|
US20020037914A1
(en)
*
|
2000-03-31 |
2002-03-28 |
Delong Mitchell Anthony |
Compositions and methods for treating hair loss using C16-C20 aromatic tetrahydro prostaglandins
|
|
US20020146439A1
(en)
*
|
2000-03-31 |
2002-10-10 |
Delong Mitchell Anthony |
Compositions and methods for treating hair loss using oximyl and hydroxylamino prostaglandins
|
|
AU2001290250A1
(en)
*
|
2000-09-21 |
2002-04-02 |
Ono Pharmaceutical Co. Ltd. |
Ep4 receptor agonists containing 8-azaprostaglandin derivatives as the active ingredient
|
|
GB0103269D0
(en)
*
|
2001-02-09 |
2001-03-28 |
Glaxo Group Ltd |
Napthalene derivatives
|
|
US6410591B1
(en)
|
2001-05-08 |
2002-06-25 |
Allergan Sales, Inc. |
3,7 or 3 and 7 thia or oxa prostanoic acid derivatives as agents for lowering intraocular pressure
|
|
US20050222094A1
(en)
*
|
2001-06-14 |
2005-10-06 |
Burk Robert M |
Treatment of inflammatory bowel disease
|
|
US20030027853A1
(en)
|
2001-06-14 |
2003-02-06 |
Allergan Sales, Inc. |
3, 7or3 and 7 thia or oxa prostanoic acid derivatives as agents for lowering intraocular pressure
|
|
US7872045B2
(en)
|
2001-06-14 |
2011-01-18 |
Allergan, Inc. |
Combination therapy for glaucoma treatment
|
|
EP1490055A1
(en)
*
|
2002-03-18 |
2004-12-29 |
Pfizer Products Inc. |
Use of selective ep4 receptor agonists for the treatment of liver failure, loss of patency of the ductus arteriosus, glaucoma or ocular hypertension
|
|
AU2003224244A1
(en)
*
|
2002-03-27 |
2003-10-13 |
Rosanto Pharmaceuticals Ltd |
Improvements in pharmaceutical compositions
|
|
EP1513589B1
(en)
|
2002-06-06 |
2010-11-10 |
Merck Frosst Canada Ltd. |
1,5-disubstituted pyrrolid-2-one derivatives for use as ep4 receptor agonists in the treatment of eye diseases such as glaucoma
|
|
US7053085B2
(en)
|
2003-03-26 |
2006-05-30 |
Merck & Co. Inc. |
EP4 receptor agonist, compositions and methods thereof
|
|
WO2004073589A2
(en)
*
|
2003-02-24 |
2004-09-02 |
Bayer Healthcare Ag |
Diagnostics and therapeutics for diseases associated with g-protein coupled receptor prostaglandin e2 ep4 (prostaglandin e2 ep4)
|
|
CA2565628A1
(en)
*
|
2004-05-03 |
2005-11-10 |
Astellas Pharma Inc. |
The combination of prostaglandin e2 receptor antagonist and renin-angiotensin system inhibitor for treating renal diseases
|
|
EP1782829A1
(en)
*
|
2004-08-10 |
2007-05-09 |
Ono Pharmaceutical Co., Ltd. |
Preventive and/or remedy for hyperkalemia containing ep4 agonist
|
|
WO2006047466A2
(en)
|
2004-10-21 |
2006-05-04 |
Duke University |
Ophthamological drugs
|
|
UY30121A1
(es)
|
2006-02-03 |
2007-08-31 |
Glaxo Group Ltd |
Nuevos compuestos
|
|
EP2094839B1
(en)
|
2006-12-08 |
2020-02-05 |
University of Rochester |
Expansion of hematopoietic stem cells
|
|
JP5069752B2
(ja)
|
2006-12-15 |
2012-11-07 |
グラクソ グループ リミテッド |
Ｅｐ４受容体アゴニストとしてのベンズアミド誘導体
|
|
GB0721611D0
(en)
|
2007-11-02 |
2007-12-12 |
Glaxo Group Ltd |
Novel compounds
|
|
US8623918B2
(en)
*
|
2008-10-29 |
2014-01-07 |
Novaer Holdings, Inc. |
Amino acid salts of prostaglandins
|
|
US8722739B2
(en)
|
2008-10-29 |
2014-05-13 |
Novaer Holdings, Inc. |
Amino acid salts of prostaglandins
|
|
CA2738045C
(en)
|
2010-05-28 |
2019-02-19 |
Simon Fraser University |
Conjugate compounds, methods of making same, and uses thereof
|
|
US9650414B1
(en)
|
2014-05-30 |
2017-05-16 |
Simon Fraser University |
Dual-action EP4 agonist—bisphosphonate conjugates and uses thereof
|
|
CN107849072B
(zh)
|
2015-06-12 |
2020-12-15 |
西蒙弗雷泽大学 |
酰胺连接的ep4激动剂-二膦酸盐化合物及其用途
|